The Sinovac COVID-19 vaccine

The Sinovac COVID-19 vaccine

ON 13 August 2021

Vaccine platform acronymIV

Vaccine platform descriptionInactivated virus

Type of candidate vaccineCoronaVac; inactivated SARS-CoV-2 vaccine (vero cell)

Number of doses – 2

ScheduleDay 0 + 14

Route of administrationIM

DevelopersSinovac Research and Development Co., Ltd

PhasePhase 4

Phase 1/2NCT04383574 | Study Report | NCT04352608 | Study Report | NCT04551547 | Study Report

Phase 2

NCT04800133
NCT04884685
NCT04979949
NCT04979949

Phase 2/3 – null

Phase 3

NCT04456595
Study Report
Study Protocol
NCT04508075
 NCT04582344
Study report
NCT04617483
NCT04651790
Study Report

Phase 4

NCT04756830**
NCT04747821**
NCT04775069
NCT04789356
NCT04754698
NCT04801888
NCT04894227
NCT04892459
NCT04911790
NCT04953325
NCT04962308

Phase not reported

ChiCTR2100045109
NCT04771559

References:

https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know


About Eleanor Harris

Hi, there. It's my blog about nutritional solutions. I post the most helpful content in this topic ❤️ I got master degree 4 years ago at University of Otago in Dunedin, New Zealand. Now i work for Danone as Nutrition Executive

View all posts by Eleanor Harris →

Leave a Reply

Your email address will not be published. Required fields are marked *